浙江新光药业股份有限公司 关于召开 2025 年第一次临时股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）第五届董事会第五次会 议审议通过了《关于提请召开公司 2025 年第一次临时股东大会的议案》，决定 于 2025 年 9 月 12 日召开公司 2025 年第一次临时股东大会，审议董事会、监事 会提交的相关议案。现将本次股东大会的有关事项通知如下： 证券代码：300519 证券简称：新光药业 公告编号：2025-025 4、会议召开的日期、时间 （1）现场会议召开时间：2025 年 9 月 12 日（星期五）下午 14:00； （2）网络投票时间：2025 年 9 月 12 日，其中： ①通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的 时间为：2025 年 9 月 12 日 9:15—9:25，9:30-11:30，13:00-15:00； ②通过深交所互联网系统投票的具体时间为：2025 年 9 月 12 日 9:15— 15:00 期间的任意时间。 5、会议的召开方式：本次 ...

Group 1 - The latest stock price of Xinguang Pharmaceutical is 20.05 yuan, an increase of 0.25 yuan from the previous trading day [1] - The stock opened at 18.86 yuan, reached a high of 20.28 yuan, and a low of 18.15 yuan, with an overall fluctuation of 10.76% throughout the day [1] - The trading volume was 260,458 hands, with a total transaction amount of 491 million yuan [1] Group 2 - Xinguang Pharmaceutical operates in the pharmaceutical manufacturing industry, specifically in the traditional Chinese medicine production sector [1] - The company is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drug formulations, and raw materials [1] - Its product range covers multiple therapeutic areas, including cardiovascular, digestive, and respiratory systems [1] Group 3 - On August 4, the stock experienced a rapid rebound during the morning trading session, with a rise of over 2% within 5 minutes [1] - As of 9:37 AM, the stock price was reported at 18.95 yuan, with a transaction amount reaching 105 million yuan [1] - In terms of capital flow, there was a net outflow of 4.5732 million yuan from the main funds on that day, accounting for 0.2% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 22.5547 million yuan, representing 0.99% of the circulating market value [1]

证券代码：300519 证券简称：新光药业 公告编号：2025-018 浙江新光药业股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召 开第五届董事会第三次会议及第五届监事会第三次会议，审议通过《关于首次公 开发行股票的部分募集资金投资项目结项并将节余募集资金永久补充流动资金及 注销部分募集资金专用账户的议案》，并于 2025 年 5 月 13 日召开的 2024 年度 股东大会审议通过了上述议案，同意公司将由公司全资子公司浙江新光医药科技 有限公司（以下简称"新光医药科技"）建设的"现代中药研发中心建设项目" 进行结项，将节余募集资金永久补充流动资金，并对相关募集资金专户进行销户 处理。具体详见公司于 2025 年 4 月 21 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于首次公开发行股票的部分募集资金投资项目结项并将节余募集资金 永久补充流动资金及注销部分募集资金专用账户的公告》（公告编号：2025- 010）。 ...

Group 1 - Ningde Times participated in the completion of the Zeyuan Fund, with a total scale of 10.128 billion yuan, increasing by 50.42% from the previous announcement [3] - Zhongjin Gold's controlling shareholder plans to inject four companies into the company to resolve competition issues, including acquiring stakes in Inner Mongolia Jintao and others [4][5] - Keli Yuan plans to invest an additional 500 million yuan in a storage industry fund, increasing its total investment to 700 million yuan [6] Group 2 - China Shenhua intends to acquire 7.43% of the National Energy Group Financial Company for 2.929 billion yuan, which is expected to increase its net profit by 97 million yuan [7] - Weir Shares plans to issue H-shares and list on the Hong Kong Stock Exchange [8] - Hualan Shares is establishing a joint venture for Tibetan medicinal baths and plaster products, with a registered capital of 7 million yuan [15] Group 3 - Yunnan Copper plans to acquire 40% of Liangshan Mining through a share issuance, with the stock resuming trading on May 26 [10] - Ruishun Technology's subsidiary plans to establish a joint venture in Malaysia to provide automation solutions [11] - ST Quanwei's stock will be subject to additional risk warnings due to ongoing litigation involving a subsidiary [12] Group 4 - Hengfeng Information's controlling shareholder has terminated the agreement to transfer part of the company's shares, with no impact on control [13] - Huadian Technology's subsidiary has not yet commenced substantial construction on a polyurethane new materials project [14] - ST Yinjian will remove the delisting risk warning and some other risk warnings, changing its stock name [38] Group 5 - China Tonghao won approximately 3.789 billion yuan in contracts in the rail transit market from March to April [39] - Intercontinental Oil and Gas plans to invest about 848 million USD in the Iraq South Basra project [40][41] - Jiaying Pharmaceutical's subsidiary signed a contract for the development of a traditional Chinese medicine innovation project [42] Group 6 - Ruidong Intelligent signed a strategic cooperation agreement with Shunde Vocational and Technical College to enhance collaboration in technology [43] - Jiaojian Co. won a bid for a drainage project worth 225 million yuan [44] - Hengshun Vinegar's controlling shareholder plans to increase its stake in the company by 50 to 100 million yuan [45]

Mergers and Acquisitions - Zhongjin Gold plans to acquire 49.34% stake in Inner Mongolia Jintao and 80% stake in Hebei Dabaiyang Gold Mine, along with 70% stakes in Liaoning Tianli and Liaoning Jinfeng Gold Mining, to resolve industry competition issues [1] - Dike Co. intends to acquire 60% stake in Zhejiang Sote for 696 million yuan, gaining control over the Solamet photovoltaic silver paste business [2] - China Shenhua plans to acquire 7.43% stake in its financial subsidiary for 2.929 billion yuan, changing the ownership structure to 60% for State Energy Investment Group and 40% for China Shenhua [3] Shareholding Changes - New Light Pharmaceutical's major shareholder plans to reduce its stake by up to 3%, equating to a maximum of 4.8 million shares [4] - Xingfa Group's supervisor increased his shareholding by 15,000 shares, amounting to 311,500 yuan, representing 0.0014% of the total shares [5] - Changhua Group's shareholders plan to reduce their holdings by up to 3%, totaling a maximum of 14.1 million shares [6] Risk Matters - ST Quanwei's stock will face additional risk warnings due to a lawsuit involving a guarantee amounting to 10.0126 million yuan, which exceeds 5% of the company's latest audited net assets [7] - Jinhua Co.'s chairman is under investigation for alleged violations related to shareholding disclosure, but this will not affect the company's daily operations [8]

Company Announcements - Weir Shares plans to issue H-shares and list on the Hong Kong Stock Exchange to accelerate international strategy and enhance overseas financing capabilities [1] - Zhongjin Gold's controlling shareholder plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues [2] - Hanchuan Intelligent has filed a lawsuit against CATL and its subsidiaries for approximately 60.88 million yuan due to payment defaults [2] - Yunnan Copper intends to acquire a 40% stake in Liangshan Mining, with stock resuming trading on May 26 [3] - China Shenhua plans to acquire a 7.43% stake in China Energy Group Financial Company for 2.929 billion yuan [3] - Dike Co. intends to acquire 60% of Zhejiang Suote for 696 million yuan to control the Solamet photovoltaic silver paste business [4] - Jin Hua Co.'s chairman is under investigation for information disclosure violations, but it will not affect the company's operations [4] Financing and Investments - Heng Rui Pharmaceutical's H-shares will be listed on May 23, 2025, with a total issuance of 225 million shares at a price of 44.05 HKD per share [23] - Ningde Times' investment fund has increased to 10.128 billion yuan, with the company's stake reduced to 6.91% [8] - Intercontinental Oil and Gas expects to invest approximately 848 million USD in the Iraq South Basra project [9] - Keli Yuan plans to invest an additional 500 million yuan in a storage industry fund, increasing its total investment to 700 million yuan [10] Project Bids and Contracts - China Communications has won important rail transit projects totaling approximately 3.789 billion yuan [22] - Anhui Construction has received multiple project bids totaling over 2 billion yuan [22] Operational Updates - Zijin Mining's Kamoa-Kakula copper mine has suspended some underground mining operations due to seismic activity, potentially impacting future production [21] - Shaanxi Natural Gas will reduce pipeline transportation prices by 0.0386 yuan per cubic meter, expected to decrease net profit by approximately 222 million yuan in 2025 [20]

Group 1 - The core point of the announcement is that a major shareholder, Hongfeng Investment, plans to reduce its stake in XinGuang Pharmaceutical by up to 4.8 million shares, which represents a maximum of 3% of the company's total share capital [1] - The reduction will occur within three months starting from 15 trading days after the announcement, utilizing both centralized bidding and block trading methods [1] - Specifically, the shareholder intends to sell up to 1.6 million shares (1% of total share capital) through centralized bidding and up to 3.2 million shares (2% of total share capital) via block trading [1]

近日，公司收到持股 5%以上股东和丰投资出具的《关于股份减持计划的告知函》。 现将相关情况公告如下： 证券代码：300519 证券简称：新光药业 公告编号：2025-017 浙江新光药业股份有限公司 关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有浙江新光药业股份有限公司（以下简称 "公司"）股份 26,780,900 股（占 公司总股本比例 16.74%）的股东嵊州市和丰投资股份有限公司（以下简称"和丰投 资"）计划于本公告披露之日起 15 个交易日后的 3 个月内以集中竞价交易方式或 大宗交易方式共计减持其持有的不超过 4,800,000 股公司股份（即不超过公司总股 本的 3%）。其中：计划于本公告披露之日起 15 个交易日后的 3 个月内以集中竞价 交易方式减持其持有的不超过 1,600,000 股公司股份（即不超过公司总股本的 1%）； 计划于本公告披露之日起 15 个交易日后的 3 个月内 ...

Core Viewpoint - Zhejiang Xinguang Pharmaceutical Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 3.00 per share, totaling RMB 48 million, approved by the shareholders' meeting on May 13, 2025 [1][2]. Summary by Sections Profit Distribution Plan - The profit distribution plan involves a cash dividend of RMB 3.00 per 10 shares, amounting to a total cash distribution of RMB 48 million (including tax) [1]. - No capital reserve will be converted into share capital, and no bonus shares will be issued. The remaining undistributed profits will be carried forward to future years [1]. Dividend Taxation - For Hong Kong market investors, QFII, RQFII, and individual investors holding pre-IPO restricted shares, the cash dividend will be RMB 2.70 per 10 shares after tax [1]. - A differentiated tax rate will apply for individual shareholders based on their holding period when transferring shares, with specific tax amounts outlined for different holding durations [2]. Key Dates - The record date for the dividend distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [2]. Distribution Method - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [2]. - The company assumes all legal responsibilities for any shortfall in cash dividends due to a decrease in shares held by shareholders during the distribution application period [2].

证券代码：300519 证券简称：新光药业 公告编号：2025-016 浙江新光药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 13 日召开的 2024 年度股东大会审议通过。现 将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司 2024 年度股东大会审议通过的 2024 年度利润分配方案为：以截至 2024 年 12 月 31 日公司总股本 16,000 万股为基数，向全体股东每 10 股派发现 金红利人民币 3.00 元（含税），合计派发现金红利人民币 48,000,000.00 元 （含税）。 本次利润分配不进行资本公积转增股本，不送红股，剩余未分配利润结转以 后年度分配。若在分配方案实施前，公司总股本发生变动的，公司将按照分配总 额不变的原则对分配比例进行调整。 2、自分配方案披露至实施期间，公司总股本未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配方案 ...